https://orcid.org/0000-0003-3521-9283
References
- Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019;11:257. doi:10.2147/CLEP.S191418
- Jaeger VKWE, Allanore Y; and the EUSTAR co-authors. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 11;2016:e0163894. doi:10.1371/journal.pone.0163894
- Van Den Hoogen F, Khanna D, Fransen J, et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747. doi:10.1002/art.38098
- Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest. 1999;116(3):715–720. doi:10.1378/chest.116.3.715
- Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40–51. doi:10.1007/s12016-018-8718-8
- Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304–320. doi:10.1016/S2213-2600(19)30480-1
- Bahmer T, Romagnoli M, Girelli F, Claussen M, Rabe KF. The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)–A practical approach for the pulmonologist. Respir Med. 2016;113:80–92. doi:10.1016/j.rmed.2016.01.019
- Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019;20(1):13. doi:10.1186/s12931-019-0980-7
- Takei R, Arita M, Kumagai S, et al. Radiographic fibrosis score predicts survival in systemic sclerosis‐associated interstitial lung disease. Respirology. 2018;23(4):385–391. doi:10.1111/resp.13175
- Tjandrawati A, Logito V, Saragih WAM, Rahmadi AR, Dewi S. Laboratory strategy for autoantibodies testing as a diagnostic marker of pulmonary fibrosis in systemic sclerosis: a preliminary study prior to cohort registry of systemic sclerosis in West Java Indonesia. Biomed Res Ther. 2021;8(8):4505–4513. doi:10.15419/bmrat.v8i8.689
- Yang H. Autoantibodies in systemic sclerosis. In: Takehara K, Fujimoto M, Kuwana M, editors. Systemic Sclerosis. Tokyo: Springer; 2016:231–247.
- Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya J-M. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012;38(2–3):J109–J119. doi:10.1016/j.jaut.2011.10.003
- É V, Bernatsky S, Hudson M, Pineau CA, Baron M. Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Res Ther. 2014;16(3):1–7.
- Aleksandrov A, Shilova L, Aleksandrov V. Oral and poster abstracts. J Scleroderma Relat Disord. 2020;5(1_suppl):1–307. doi:10.1177/2397198319898367
- Didier K, Bolko L, Giusti D, et al. Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol. 2018;9:541. doi:10.3389/fimmu.2018.00541
- Wong HB, Lim GH. Measures of diagnostic accuracy: sensitivity, specificity, PPV and NPV. Proc Singapore Healthc. 2011;20(4):316–318. doi:10.1177/201010581102000411
- Varga JLR. Etiology and pathogenesis of systemic sclerosis. In: Rheumatology. Philadelphia: Elsevier; 2015:1177–1185.
- Simon R. Sensitivity, specificity, PPV, and NPV for predictive biomarkers. JNCI. 2015;107:8. doi:10.1093/jnci/djv153
- Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012;14(2):R50. doi:10.1186/ar3763
- Mecoli C, Gutierrez-Alamillo L, Yang Q, et al. PM-Scl and Th/To in systemic sclerosis: a comparison of different autoantibody assays. Clin Rheumatol. 2021;40:1–7.